3SBio Inc - Asset Resilience Ratio
3SBio Inc (83B) has an Asset Resilience Ratio of 10.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of 3SBio Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how 3SBio Inc's Asset Resilience Ratio has changed over time. See 3SBio Inc net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down 3SBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of 3SBio Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.86 Billion | 10.64% |
| Total Liquid Assets | €3.86 Billion | 10.64% |
Asset Resilience Insights
- Moderate Liquidity: 3SBio Inc has 10.64% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
3SBio Inc Industry Peers by Asset Resilience Ratio
Compare 3SBio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
SillaJen Inc
KQ:215600 |
Biotechnology | 50.41% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
ABL Bio Inc
KQ:298380 |
Biotechnology | 0.69% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for 3SBio Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for 3SBio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.64% | €3.86 Billion ≈ $4.51 Billion |
€36.25 Billion ≈ $42.38 Billion |
-4.93pp |
| 2024-12-31 | 15.57% | €3.77 Billion ≈ $4.41 Billion |
€24.21 Billion ≈ $28.31 Billion |
+1.59pp |
| 2023-12-31 | 13.98% | €3.30 Billion ≈ $3.86 Billion |
€23.63 Billion ≈ $27.62 Billion |
-8.13pp |
| 2022-12-31 | 22.11% | €4.86 Billion ≈ $5.68 Billion |
€21.99 Billion ≈ $25.71 Billion |
+12.22pp |
| 2021-12-31 | 9.89% | €1.90 Billion ≈ $2.22 Billion |
€19.21 Billion ≈ $22.46 Billion |
+2.69pp |
| 2020-12-31 | 7.20% | €1.27 Billion ≈ $1.49 Billion |
€17.68 Billion ≈ $20.67 Billion |
+4.01pp |
| 2019-12-31 | 3.19% | €472.16 Million ≈ $552.01 Million |
€14.81 Billion ≈ $17.31 Billion |
+2.70pp |
| 2018-12-31 | 0.49% | €68.13 Million ≈ $79.65 Million |
€13.84 Billion ≈ $16.18 Billion |
-4.63pp |
| 2017-12-31 | 5.12% | €704.56 Million ≈ $823.71 Million |
€13.75 Billion ≈ $16.08 Billion |
+1.84pp |
| 2016-12-31 | 3.28% | €362.17 Million ≈ $423.42 Million |
€11.04 Billion ≈ $12.91 Billion |
-- |
About 3SBio Inc
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thromboc… Read more